Opportunities
Search

Buyer: Stockholms läns sjukvårdsområde | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: Centre Hospitalier Alpes Léman, établissement support du GHT Léman Mont-Blanc | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: УНИВЕРСИТЕТСКА МНОГОПРОФИЛНА БОЛНИЦА ЗА АКТИВНО ЛЕЧЕНИЕ "СВ. ИВАН РИЛСКИ" ЕАД | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: AB „Kelių priežiūra“ | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The NOFO solicits R61 applications for early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Technologies proposed for development may have potential for widespread applicability but must be focused for this program on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites grant applications proposing exploratory research projects focused on further development and technical validation of emerging technologies offering novel capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens used for basic, clinical, or epidemiological cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous technical validation to encourage adoption by the research community. Well-suited applications must propose the development of technologies that offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Buyer: Lesy České republiky, s.p. | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-11-11

Buyer: INST NAT DES SCIENCES APPLIQUEES LYON | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-12

Buyer: Miljødirektoratet | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-13

Buyer: Cargotor Sp. z o.o. | Notice type: cn-standard | Procedure: comp-dial | Contract: works | Deadline: 2026-11-13

Buyer: SADEV 94 | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-13